CLINICAL_TRIALS
trial_result
· 2008-10-24
Clinical Trial Update: A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) [Phase 1]
Summary
Phase I trial evaluating autologous CLL B cells engineered to express CD154 (ISF35); study completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memgen, LLC | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED